Show simple item record

dc.contributor.authorSwartz, Melody A.
dc.contributor.authorIrvine, Darrell J
dc.contributor.authorSzeto, Gregory
dc.date.accessioned2014-12-01T18:53:03Z
dc.date.available2014-12-01T18:53:03Z
dc.date.issued2013-10
dc.date.submitted2013-02
dc.identifier.issn1476-1122
dc.identifier.issn1476-4660
dc.identifier.urihttp://hdl.handle.net/1721.1/91967
dc.description.abstractVaccines aim to protect against or treat diseases through manipulation of the immune response, promoting either immunity or tolerance. In the former case, vaccines generate antibodies and T cells poised to protect against future pathogen encounter or attack diseased cells such as tumours; in the latter case, which is far less developed, vaccines block pathogenic autoreactive T cells and autoantibodies that target self tissue. Enormous challenges remain, however, as a consequence of our incomplete understanding of human immunity. A rapidly growing field of research is the design of vaccines based on synthetic materials to target organs, tissues, cells or intracellular compartments; to co-deliver immunomodulatory signals that control the quality of the immune response; or to act directly as immune regulators. There exists great potential for well-defined materials to further our understanding of immunity. Here we describe recent advances in the design of synthetic materials to direct immune responses, highlighting successes and challenges in prophylactic, therapeutic and tolerance-inducing vaccines.en_US
dc.description.sponsorshipUnited States. Dept. of Defense (contract W911NF-13-D-0001)en_US
dc.description.sponsorshipUnited States. Dept. of Defense (contract W911NF-07-D-0004)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (AI095109)en_US
dc.description.sponsorshipBill & Melinda Gates Foundationen_US
dc.description.sponsorshipRagon Institute of MGH, MIT, and Harvarden_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (AI091693)en_US
dc.description.sponsorshipHoward Hughes Medical Institute (Investigator)en_US
dc.description.sponsorshipCarigest SAen_US
dc.language.isoen_US
dc.publisherNature Publishing Groupen_US
dc.relation.isversionofhttp://dx.doi.org/10.1038/nmat3775en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourcePMCen_US
dc.titleEngineering synthetic vaccines using cues from natural immunityen_US
dc.typeArticleen_US
dc.identifier.citationIrvine, Darrell J., Melody A. Swartz, and Gregory L. Szeto. “Engineering Synthetic Vaccines Using Cues from Natural Immunity.” Nature Materials 12, no. 11 (October 23, 2013): 978–990.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Materials Science and Engineeringen_US
dc.contributor.departmentRagon Institute of MGH, MIT and Harvarden_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorIrvine, Darrell J.en_US
dc.contributor.mitauthorSzeto, Gregory Leeen_US
dc.relation.journalNature Materialsen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsIrvine, Darrell J.; Swartz, Melody A.; Szeto, Gregory L.en_US
dc.identifier.orcidhttps://orcid.org/0000-0001-7604-1333
mit.licensePUBLISHER_POLICYen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record